By contrast, associations of dasatinib sensitivity with stronger upregulation of SIRT1, SIRT2, and SIRT5 were unexpected, since these genes have tumour promoting effects, and their downregulation positively affects cancer treatment outcomes [13,14,32,78,79]. This evidence concerns the gene SIRT2 and neoplasm.